|
|
|
- ふみな ほがり
- 9 years ago
- Views:
Transcription
1 Establishment and progress of Sendai virus engineering
2
3
4
5
6
7
8
9
10
11 2) Schnell, M. J., Mebatsion, T., Conzelmann, K.-K.: EMBO J., 13, (1994) 3) Kato, A. et al.: Genes Cells, 1, (1996) 4) Nagai, Y. : Rev. Med. Virol., 9,83-99(1999) 5) Li., H.-O. et al.: J. Virol., 74, (2000) 6) Kato, A. et al.: EMBO J., 16, (1997) 7) Kato, A. et al.: J. Virol., 71, (1997) 8) Huang, C. et al.: J. Virol., 74, (2000) 9) Kurotani, A. et al.: Genes Cells, 3, (1998) 10) Hasan, M. K. et al.: J. Virol., 74, (2000) 11) Sakaguchi, T. et al.: J. Virol., 79, (2005) 12) Gotoh, B. et al.: FEBS Lett., 459, (1999) 13) Kato, A. et al.: J. Virol., 75, (2001) 14) Kato, A. et al.: J. Virol., 76, (2002) 15) Takeuchi, K. et al.: Genes Cells, 6, (2001) 16) Kato, A, et al.: J. Virol., 78, (2004) 17) Nagai, Y., Kato, A. : Curr. Top. Microbiol. Immunol., 283, (2004) 18) Kato, A. et al.: J. Virol., 73, (1999) 19) Hu, C. et al. : Virology, 263, (1999) 20) Sakaguchi, T. et al.: Virology, 235, (1997) 21) Nagai, Y., Klenk, H.-D., Rott, R.: Virology, 72, (1976) 22) Nagai, Y. : Trends Microbiol., 1, (1993) 23) Peeters, B. P. H. et al. : J. Virol., 73, (1999) 24) Hasan, M. K. et al.: J. Gen. Virol., 78, (1997) 25) Yu, D. et al.: Genes Cells, 2, (1997) 26) Yonemitsu, Y. et al.: Nature Biotechnol., 18, (2000) 27) Slobod, K. S. et al.: Vaccine, 22, (2004) 28) Masaki, I. et al. : Circ. Res., 17, (2002) 29) Iwadate, Y. et al. : Clin. Cancer Res., 11, (2005) 30) Inoue, M. et al.: J. Virol., 77, (2003) 31) Gotoh, B. et al.: EMBO J., 9, (1990) 32) Kinoh,H.etal.: Gene Ther., 11, (2004) 33) Kano, M. et al.: AIDS, 14, (2000) 34) Matano, T. et al.: J. Virol., 75, (2001) 35) Feinberg, M. B., Moore, J. P.: Nature Med., 8, (2002) 36) Matano, T. et al.: J. Exp. Med., 199, (2004) 37) Takimoto, T. et al.: J. Virol., 78, (2004) 1) Shioda, T., Iwasaki, K., Shibuta, H.: Nucleic Acid. Res., 14, (1986)
Short Review Hidenori Takagi, Fumio Takaiwa, E-mail : [email protected] 13) Hirahara, K. et al. : J. Allergy Clin. Immunol., 102, 961-967 (1998) 14) Takagi, H. et al.: Proc. Natl. Acad. Sci.
437“ƒ
et al., et al., et al., et al., et al., et al., 2 et al., et al., et al., Lancet Pharmacol Res. et al. Jpn J Cancer Res. et al. Jpn J Cancer Res. et al. Tohoku J Exp Med. et al. Jpn Circ J. et al. Cancer
表1.eps
Vol.1 C ontents 1 2 cell-free EMBO J Proc. Natl. Acad. Sci. USA NatureEMBO J 3 RNA NatureEMBO J Nature EMBO J 4 5 HCV HCV HCV HCV RNA HCV in situ 6 7 8 Nat Struct Mol Biol J Biol Chem Nat Commun J Virol
2009 Aida et al. Caries Res 2006;40 2000 100 % 78.7 88.0 96.6 98.8 98.8 98.8 100.0 100.0 100 75 69.4 50 75.3 74.8 73.3 73.1 73.0 72.4 71.8 71.7 51.7 40.2 69.4 68.8 73.6 25 22.3 32.8 21.9 22.9 22.1
(1982) 4) Bennett, J. W. : in The 10th International Congress for Culture Collections. (Okuda, T., Bennett, J. W. ed.), pp. 54-57(2004) 5) Machida, M.: Adv. Appl. Microbiol. 51, 81-106 (2002) 6) Florea,
Various function and toxicity of iron Key words 1) Hentze, M. W. et al: Cell, 117, 285-297 (2004) 2) Ganz, T.: Blood, 102, 783-788 (2003) 3) Nemeth, E. et al.: Science, 306, 2090-2093 (2004) 4) Hentze,
/‚“1/ŒxŒ{‚×›î’æ’¶
60 1 pp.3-8 2010 1. H1N1 1) 2) 3) 4) ERATO 2009 H1N1 21 H1N1 HA PB2 2009 3 Pandemic H1N1 2009 WHO 6 11 21 2009 11 2010 4 21 H1N1 H1N1 2009 4 15 CDC 108-8639 4-6-1 TEL: 03-5449-5281 FAX: 03-5449-5408 E-mail:
RX501NC_LTE Mobile Router取説.indb
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 1 2 3 4 5 6 7 8 19 20 21 22 1 1 23 1 24 25 1 1 26 A 1 B C 27 D 1 E F 28 1 29 1 A A 30 31 2 A B C D E F 32 G 2 H A B C D 33 E 2 F 34 A B C D 2 E 35 2 A B C D 36
1) van Meer, G., Op den Kamp, J. A.: J. Cell. Biochem., 19, 193-2040982) 2) Gaffet, P., Bettache, N., Bienvenue, A.: Biochemistry, 34, 6762-6769(1995) 3) Sims, P. J., Wiedmer, T.: Thromb. Haemost., 86,
Database Center for Life Science Online Service Virus infection and interferon system
Virus infection and interferon system cing IFN-(3 ) /TICAM 1 (Toll-interleukin 1 receptor do main-containing adaptor molecule 1), TRAF6 (tumor necrosis factor receptor associated factor 6), TAB1 (TAK1-binding
Complex sleep apnea syndrome and sleep disordered breathing in patients with cardiovascular disease V o l. 4 1 N o. 3 ( 2 0 0 9 ) V o l. 4 1 N o. 3 ( 2 0 0 9 ) V o l. 4 1 N o. 3 ( 2 0 0 9 ) Sleep J Clin
Kazumitsu Ueda, [Department of Applied Life Science, Kyoto University Graduate School of Agriculture, Kitashirakawa, Sakyo-ku, Kyoto 606-01, Japan] Molecular Mechanisms for Drug Transport by MDR1/P-glycoprotein
Review Column 1) Extavour, C. G., Akam, M. : Development, 130, 5869-5884 (2003) 2) Saitou, M. et al.: Philos. Trans. R. Soc. Lond. B. Biol. Sci., 358,1363-1370(2003) 3) Eddy, E. M. : Int. Rev.
日本皮膚科学会雑誌第121巻第11号
β Clin Rheumatol Arthritis Rheum Am J Cardiol J Rheumatol J Rheumatol Arthritis Rheum Arthritis Rheum Arthritis Rheum Rheumatology Oxford Rheumatology Oxford Br J Dermatol Arch Dermatol Ann Rheum Dis
untitled
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Int J Radiat Oncol Biol Phys 49 Cancer 101 Int J Radiat Oncol Biol Phys 60 Chest 124 Int J Radiat Oncol Biol Phys 56 Int J Radiat Oncol Biol Phys 49 Chest 124 Int J
Stress-responsive MAP kinases 15) Lu, H. T., Yang, D. D., Wysk, M., Gatti, E., Mellman, I., Davis, R. J., Flavell, R. A. : EMBO J., 18,1845-1857 (1999) 16) Lu, B., Yu, H., Chow, C., Li, B., Zheng,
VOL33NO.3/2010 A B A B p-erk1/2 Time (min) 0 1 2 5 10 15 30 60 90 120 Erk1/2 Time (min) 0 1 2 5 10 15 30 60 90 120 p-vasp VASP C D enos/gapdh x-fold vs sham 2.0 1.5 1.0 0.5 * 0 ANP (-) (+) (-)
24 10 QOL 6) 7) 2 8,9) Cry j 1 10,11) Cry j 2 12,13) Cha o 1 14) Cha o 2 15) Cry j 1 Cha o 1 80% Cry j 2 Cha o 2 74% T B Cry j 1 Cha o 1 IL-5 1) 1,16)
JJIAO 36 1 : 23 28, 2018 総 説 1,2 1 2 Cha o 3 ImmunoCAP 2 87.5% Cha o 3 IgE Cha o 3 IgE Cha o 1 ImmunoCAP Cha o 3 IL-5 Cha o 3 Cha o 3 IgE, Immunoglobulin E; PAS, Periodic acid-schiff; SDS-PAGE, Sodium
untitled
HBV HBV (1964) HDV (1977) HCV (1988) 2009 Yotsuyanagi H et al. J Med Virol 2005 Yotsuyanagi H et al. J Hepatol 2002 Universal vaccination (UV) 45 HB 2009 1/3 Progress Toward the Elimination
The Heart Healthy Tocotrienol Complex Tocomin SupraBio
The Heart Healthy Tocotrienol Complex Tocomin SupraBio The Heart Healthy Tocotrienol Complex Tocomin SupraBio 1. Fact Sheet No. 317; World Health Organization (WHO), 2007 2. LLOYD-JONES D. et al. Circulation
Database Center for Life Science Online Service
アデノウイルスベクターの改良と応用 7 ン トネ ガ テ ィ ブ を用 い てRel NF-κBの シグナル の不 活 化 を 試 み た そ の 結 果 IκBの ド ミナ ン トネ ガ テ ィ ブ を ニ ワ ト リ胚 肢 芽 に 接 種 した 群 で は 発 現 率 は低 い もの の 四 肢 の 形 成 阻 害 が 認 め られ この 結 果 は頂 堤 AER)を 除 去 した も の の表
9) McKenna, N. J., O'Malley, B. W. : Cell, 108,465-474 (2002) 10) Hu, X., Lazar, M. A. : Nature, 402, 93-96 (1999) 11) Lanz, R. B., McKenna, N. J., Onate, S. A., Albrecht, U., Wong, J., Tsai, S. Y., Tsai,
Kazumitsu Ueda, E-mail : [email protected] http : //cseika-1, kais.kyoto-u.ac.j p Molecular mechanism of multidrug transporter MDR I : ABC in host-defense machinery 32P-ATP 1) Chen, C., Chin,
Teru Ogura, Tomoko Yamada-Inagawa, E-mail : [email protected] AAA family ATPases : ring-shaped chaperones which catalyze energy-dependent conformational changes of proteins 29) Braun, S.,
2
1999 No. 5 CHAPERONE NEWSLETTER CONTENTS 2 3 4 JEM JEM JEM, SEC, SCJ JEM JEM SCJ jem, scj 5 in vitro S. cerevisiae 6 K 7 in vitro Cell Mol. Cell in vitro 8 9 E. coli E. coli 10 in vitro ssc - b 11 in vivo
Minamiooya, Machida, Tokyo 194, Japan] RNA World, A Key Step in the Origin of Life : Inspection from the View Point of Biological Evolution 1) Crick, F. H. C.: Sym. Soc. Exp. Biol., 12, 548-555
日本皮膚科学会雑誌第122巻第2号
J Dermatol Sci Vitam Horm NEnglJMed Lancet J Clin Invest Antitoxid Redox Signal Diabetes Metab Res Rev Diabetes Care Diabet Med Diabetes care Diabetes Care J Foot Ankle Surg Wound Repair Regen Lancet Foot
がん患者の終末期ケアにおける通所リハビリテーションの役割 介護保険によるがん終末期ケアの可能性
2 3 3 6 7 49 53 13 61 22 27 65 68 34 47 71 73 4 5 7 6 8 9 10 11 12 13 14 15 44 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4
- 2 -
- 1 - - 2 - - 3 - - 4 - - 5 - - 6 - - 7 - - 8 - - 9 - A) B) C) D) E) F) - 10 - G) H) I) J) P - 11 - 001 1,416,0003/4 1,062,000 002 100,000 50,00023 1,150,000 2,100,000 200,000+ 100,0000.9 1,600,000 JA
Sulfonylurea Receptors Pancreatic Type: SUR1 Cardiac Type: SUR2A Smooth Muscle Type: SUR2B Kir Channels uka-rp-1/kir6.1 BIR/Kir6.2 1) Ho K, et al : Cloning and expression of an inwardly rectifying ATP-regulated
THOMSON REUTERS PRESENTATION TEMPLATE
JCRW の利用方法について インパクトファクター及びその他の指標について JCRW の利用方法について インパクトファクターとは? 2009 年 10 月 8 日 トムソンロイター 甲斐真佐美 [email protected] TEL: 03-5218-6507 この講習会の目的 Journal Citation Reports の基本操作を覚える インパクトファクターの作られ方とその意味を正しく理解する
CAR-T実施
Building a Clinical CAR-T Program - Jichi Medical University Experience l l l Anti-CD3/28 mabs & IL-2: 29% Anti-CD3/28 beads: 66% Retroviral: 41% Lentiviral: 54% T-Flasks: 22% Static Culture Bags: 35%
日本皮膚科学会第121巻第9号
Appl Nurs Res Wound Repair Regen Int Wound J Adv Skin Wound Care Ostomy Wound Manage Wound Repair Regen Int J Nurs Stud JAdvNurs Visual Dermatology J Adv Nurs Appl Nurs Res Cochrane Database Syst Rev
H1-P15
72 January 2009 72 January 2009 72 January 2009 2008 GFP GFP 1992 Prasher cdna GFP Aequorea victoria GFP cdna in vivo EGFP GFP FACS GFP GFP GFP GFP 1. Prasher, D.C., et al. 1992. Primary structure of the
untitled
1 4 4 6 8 10 30 13 14 16 16 17 18 19 19 96 21 23 24 3 27 27 4 27 128 24 4 1 50 by ( 30 30 200 30 30 24 4 TOP 10 2012 8 22 3 1 7 1,000 100 30 26 3 140 21 60 98 88,000 96 3 5 29 300 21 21 11 21
4) H. Takayama et al.: J. Med. Chem., 45, 1949 (2002). 5) H. Takayama et al.: J. Am. Chem. Soc., 112, 8635 (2000). 6) H. Takayama et al.: Tetrahedron Lett., 42, 2995 (2001). 9) M. Kitajima et al: Chem.
et al No To Shinkei Clin Neurol Neurology et al J Neurosurg et al Arch Neurol et al Angiology
37 Recommendations for the Management of Moyamoya Disease A Statement from Research Committee on Spontaneous Occlusion of the Circle of Willis (Moyamoya Disease) Research on intractable diseases of the
A
ASD PTSD K6/K10 IES-R PTSD B.Raphael J.S.Tyhust 1225 75 1225 A. 3 B. C. 90 A. B. C. D. PTSD PTSD PTSD ASD PTSD ASD 4 2 4 PTSD / ASD 4 PTSD 20 80 1 Cf. Horowitz 7 PTSD PTSD PTSD 1317 PTSD ASD PTSD 1 1.5~5%
細胞増殖測定細胞染色プロトコル
Cell Counting Kit Cell Counting Kit -8 3 Cell Counting Kit -F -Cellstain- -Cellstain- -Cellstain- Calcein-AM solution -Cellstain- CytoRed solution -Cellstain- BCECF-AM special packaging -Cellstain- -Cellstain-
! 1Munderl P et al. Survival and causes of death, 2 years after Introduction of antiretroviral therapy in Africa. XVI International AIDS Conference, 2006, Abstract THLB0208. 2Walensky RP et al. The
; cm 4. ; 2. ; 3. ; 5. 2 ; 120 ng/ml Mφ 6 7, 8 9
32, 21-25, 2012 CASLE 1 1 80 26 6 5 4 cm 1 2 CEA 3 4 CEA 2 44 22 2 3 1.5 cm 22 1. 1 ; 6 5 4 cm 4. ; 2. ; 3. ; 5. 2 ; 120 ng/ml 0-40 5 Mφ 6 7, 8 9 23 6. ; 9. ; 7. ; 10. ; 8. 7 10 CK3 CK3 24 1,2 3 2 8% 4,5
化学療法剤の適切な使い方について
1 2 3 4 5 6 7 Che E, in Cancer: Principles & Practice of Oncology (7th ed) in Devita, 2005 Marangolo M, Oncol Rep, 2006 hryniuk WM, Important Adv Oncol, 1988 8 Cancer: Principles & Practice of Oncology
2
1 2 3 4 5 6 7 8 9 10 11 12 13 14 10mSv 15 16 17 4.46 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 3.8 2.07 2.91 1.37 2.3 1.31 1.84 1.56 1.2 1.33 2.03 0.5 1000 4000mSv 1000 4000mSv Preston et al. Radiat Res 168: 1 64,